Evidence
Front Microbiol. 2023 Dec 6;14:1285473. doi: 10.3389/fmicb.2023.1285473. eCollection 2023.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a common chronic hepatic disorder with the potential to progress to hepatic fibrosis, hepatic cirrhosis, and even hepatocellular carcinoma. Activation of hepatic macrophages, important innate immune cells predominantly composed of Kupffer cells, plays a pivotal role in NAFLD initiation and progression. Recent findings have underscored the regulatory role of microbes in both local and distal immune responses, including in the liver, emphasizing their contribution to NAFLD initiation and progression. Key studies have further revealed that gut microbes can penetrate the intestinal mucosa and translocate to the liver, thereby directly influencing hepatic macrophage polarization and NAFLD progression. In this review, we discuss recent evidence regarding the translocation of intestinal microbes into the liver, as well as their impact on hepatic macrophage polarization and associated cellular and molecular signaling pathways. Additionally, we summarize the potential mechanisms by which translocated microbes may activate hepatic macrophages and accelerate NAFLD progression.
PMID:38125578 | PMC:PMC10731260 | DOI:10.3389/fmicb.2023.1285473
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Gut microbe and hepatic macrophage polarization in non-alcoholic fatty liver disease
🌐 90 Days
VR Related Evidence Matrix
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Bacteroides and NAFLD: pathophysiology and therapy
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- The gut-liver axis in fatty liver disease: role played by natural products
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Hypoxia-inducible factor-2alpha promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Emerging roles of RNA-binding proteins in fatty liver disease
- Bacteroides fragilis aggravates high-fat diet-induced non-alcoholic fatty liver disease by regulating lipid metabolism and remodeling gut microbiota
- Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis
- Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells
- Gene-by-Environment Interaction in Non-Alcoholic Fatty Liver Disease and Depression: The Role of Hepatic Transaminases
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Vitamin D(3) exacerbates steatosis while calcipotriol inhibits inflammation in non-alcoholic fatty liver disease in Sod1 knockout mice: a comparative study of two forms of vitamin D
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Lactiplantibacillus plantarum ZDY2013 Inhibits the Development of Non-Alcoholic Fatty Liver Disease by Regulating the Intestinal Microbiota and Modulating the PI3K/Akt Pathway
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
- Si-Wu-Tang attenuates hepatocyte PANoptosis and M1 polarization of macrophages in non-alcoholic fatty liver disease by influencing the intercellular transfer of mtDNA
- Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review)
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Novel blood and tissue-based mitochondrial D-loop mutations detected in an Iranian NAFLD patient cohort
- Correlation between magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver biopsy to assess hepatic steatosis in obesity
- The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Fructose regulates the pentose phosphate pathway and induces an inflammatory and resolution phenotype in Kupffer cells
- Fructose regulates the pentose phosphate pathway and induces an inflammatory and resolution phenotype in Kupffer cells
- Nanoparticles alleviate non-alcoholic steatohepatitis via ER stress sensor-mediated intestinal barrier damage and gut dysbiosis
- Adrenarche-accompanied rise of adrenal sex steroid precursors prevents NAFLD in Young Female rats by converting into active androgens and inactivating hepatic Srebf1 signaling
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis
- Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- Integrating network pharmacology and experimental validation reveals therapeutic effects of D-mannose on NAFLD through mTOR suppression
- Hepatic transcriptome discloses the potential targets of Xuefu Zhuyu Decoction ameliorating non-alcoholic fatty liver disease induced by high-fat diet
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Chronic exposure to ambient air pollution and the risk of non-alcoholic fatty liver disease: A cross-sectional study in Taiwan and Hong Kong
- Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses
- Trimethylamine N-oxide ameliorates hepatic damage including reduction of hepatic bile acids and cholesterol in Fxr-null mice
Evidence Blueprint
Gut microbe and hepatic macrophage polarization in non-alcoholic fatty liver disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Gut microbe and hepatic macrophage polarization in non-alcoholic fatty liver disease
🌐 365 Days
VR Related Evidence Matrix
- Macrophages and the development and progression of non-alcoholic fatty liver disease
- Galectin-12 modulates Kupffer cell polarization to alter the progression of non-alcoholic fatty liver disease
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Bacteroides and NAFLD: pathophysiology and therapy
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Major roles of kupffer cells and macrophages in NAFLD development
- The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Ambiguous Pathogenic Roles of Macrophages in Alcohol-Associated Liver Diseases
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Invariant natural killer T cells drive hepatic homeostasis in Non-alcoholic fatty liver disease via sustained IL-10 expression in CD170+ Kupffer cells
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis
- Phospholipid metabolism in the liver - Implications for phosphatidylserine in non-alcoholic fatty liver disease
- Vitamin D/Vitamin D receptor pathway in nonalcoholic fatty liver disease
- Fructose Aggravates Copper-deficiency-induced Non-alcoholic Fatty Liver Disease
- From complement to complosome in non-alcoholic fatty liver disease: When location matters
- The gut-liver axis in fatty liver disease: role played by natural products
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways
- Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease
- NLRP3 inflammasome in hepatic diseases: A pharmacological target
- Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
- Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease
- A bibliometric analysis of macrophages associated with non-alcoholic fatty liver disease research from 2005 to 2023
- Research progress of traditional Chinese medicine in improving hepatic fibrosis based on inhibiting pathological angiogenesis
- Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
- Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice
- Cholesterol Exacerbates the Pathophysiology of Non-Alcoholic Steatohepatitis by Upregulating Hypoxia-Inducible Factor 1 and Modulating Microcirculatory Dysfunction
- Hypoxia-inducible factor-2alpha promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
- Corrected and republished from: Metabolic associated liver disease
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- Escherichia coli promotes endothelial to mesenchymal transformation of liver sinusoidal endothelial cells and exacerbates non-alcoholic fatty liver disease via its flagellin
- Liver fat as risk factor of hepatic and cardiometabolic diseases
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- The effect of liver disease on hepatic microenvironment and implications for immune therapy
- Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma
- Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
- The critical role of BTRC in hepatic steatosis as an ATGL E3 ligase
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Metformin: update on mechanisms of action on liver diseases
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Dissecting the role of cadmium, lead, arsenic, and mercury in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
- Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach
- Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- Glucosinolates Extracts from Brassica juncea Ameliorate HFD-Induced Non-Alcoholic Steatohepatitis
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- An optimized protocol for isolation of hepatic leukocytes retrieved from murine and NASH liver biopsies
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Modelling porcine NAFLD by deletion of leptin and defining the role of AMPK in hepatic fibrosis
- From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients